{"name":"Joyce O'Shaughnessy","slug":"joyce-o-shaughnessy","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Cisplatin & Nab Paclitaxel","genericName":"Cisplatin & Nab Paclitaxel","slug":"cisplatin-nab-paclitaxel","indication":"Ovarian cancer","status":"phase_2"}]}],"pipeline":[{"name":"Cisplatin & Nab Paclitaxel","genericName":"Cisplatin & Nab Paclitaxel","slug":"cisplatin-nab-paclitaxel","phase":"phase_2","mechanism":"Cisplatin is a platinum-based alkylating agent that cross-links DNA, thereby inhibiting DNA replication and transcription. Nab-paclitaxel is a nanoparticle albumin-bound formulation of paclitaxel, which inhibits microtubule dynamics.","indications":["Ovarian cancer","Breast cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPM05oNEVUWTBER0Y0Ynh3UERpcWRIN0lIdHZBMHE1TlBlMm1xU2M0WWVOQlU3ZnlrSkVxc0VDbHpJeUs5dmlmOHNqcGVJQWhSLW5vZ0lqdU9CXzQ3VDBDYW91QzE0R0xKb1U3TFljQVhQcGQzZmVyQ2VramYwdjNJU0pjSk96MWU4cmk1MXM5X2FycmpQYmc0UkRRanlKX28xUDZzTi1lRFlHcmxlUGc?oc=5","date":"2026-03-11","type":"pipeline","source":"Medscape Reference","summary":"Adjuvant Targeted Therapies in High-Risk HR+/HER2- Early Breast Cancer - Medscape Reference","headline":"Adjuvant Targeted Therapies in High-Risk HR+/HER2- Early Breast Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQckVzRTUxTndnRXJwMXdRTnZhNTBJVXZldUhsQWFmR3VUSXNGQThCNHVSaTJERmpYWjBlcmJyYlNGSmc2a3RCMHlPbkU4U09DODZQX1o0b3ZzWE5FdlJ5dDBHS3NsRzFCTGZoRzhuam5NQnk0ZTk5eGhqaWVpcm1Jb1h3bHptSFRacXdjQjlBZkw2ZlpjRHNfNTh0bE1zTHpIVnVNdTNxUWtDTkd4aHNwd3VtcjdJUHoxTlltWFJpWkUxVGs?oc=5","date":"2026-02-04","type":"pipeline","source":"CSRwire","summary":"The Next Revolution in Breast Cancer Research, According to World-Renowned Breast Oncologist, Dr. Joyce O’Shaughnessy - CSRwire","headline":"The Next Revolution in Breast Cancer Research, According to World-Renowned Breast Oncologist, Dr. Joyce O’Shaughnessy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxPYnQ4ZEhUWVlYV0swSG8tdnBXbE9SeURhX3BTTEhYVjJsTjAwRVQzSktrOFdTdks5UVpzYXdRMkxVcm1TVkZRN0Y1SWpGY1ItckJNRG9SclV4anhxcjZnZVBJTktsZVBpajlQdWJTd0s3LU9XR0Q3X3M4RWlzWnZvZ2ZDcGlacmt1akZKMWNsT091WjBaVXZLckRpOHI4WVdvUXBhMndZN01FQWc0azRSamtKbUNGb3lxc3A3ODN3NmVIcVVDRE9lTkZn?oc=5","date":"2025-12-09","type":"pipeline","source":"My Sweet Charity","summary":"Celebrating Women's Patron Party Was Jammed With Fans Of The Little Giant Dr. Joyce O’Shaughnessy - My Sweet Charity","headline":"Celebrating Women's Patron Party Was Jammed With Fans Of The Little Giant Dr. Joyce O’Shaughnessy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxOZVpwUVVsdHhUWkxYMDc2R21acFhRMU1OSnlTN1dZMDZ5R04xTnlOVTBpU1RnNlR3Q053UjY5S1Z2LWdnUlBUOEw0MVhpdmtCRXpSYVM3R3NPN0dSXzZ2M1Q0cTZmZGo5T2RVTTd2TXJtc2lhY3l6emwxbGEzcUdteHlLMXVzWGFUNTQ5QUc2MjdGNkVMblE5blZvZTVkdW45NC1EVWQ4ejUxQXVSSF9UUFQ4SVBxYTZRdjRNdUJhNC1UOTRVTk1ORnk1VEw?oc=5","date":"2025-08-22","type":"pipeline","source":"OncLive","summary":"Genomic Tests for HR+/HER2– Early Breast Cancer Show Utility Beyond Predicting Prognosis - OncLive","headline":"Genomic Tests for HR+/HER2– Early Breast Cancer Show Utility Beyond Predicting Prognosis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQQWlReDJ6c281WjhhR1pLbzI4TS1WWk5hSXVwbDhTZ1daMEpiNXdLOE9UN1NyMGJKYTd4SE93Z2IxNjNreDJSY3lraTFYWUhkYzhWYlppaUlHNWcxdko0ZjBDdmJKMmt1X0JSODA2WjBZcWlTbF9jNk00NmdVRkp2TEZDRTNOSUJvXzFVN2pZalluUDJlbXQwbQ?oc=5","date":"2024-10-21","type":"pipeline","source":"OncLive","summary":"Role of PI3K/AKT/PTEN Pathway in HR+/HER2- Advanced Breast Cancer - OncLive","headline":"Role of PI3K/AKT/PTEN Pathway in HR+/HER2- Advanced Breast Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTFBrRlA4TXdaTkFjTHlwSExQV2hza0RBUFJacXotVzBLa1ViOVIwMk0zSG00TnBVLUI5dEhQZ1Z1WnpyODVRNnBIaXgxQ2VsYllmNHZwTWl3WkdSRElibEZVWHRGSUJNU3VqMG43MWFIeWkyUQ?oc=5","date":"2024-10-21","type":"trial","source":"OncLive","summary":"Overview of the CAPItello-291 Trial - OncLive","headline":"Overview of the CAPItello-291 Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxNVi1rZ2Yzc1dfdnBkVDVqVzdxS0pSZzJzNThvemZ2aEprZmVxRDg5X3VHS01KZC1mcENNLWZod0I3eWh2Qmh6d1dTRmYwWWVENjZzOExTaUVKRUk1X0ZzbkNuYU5va2xWRHhHNS14eHpjMkswdkg2dFdBd2VJR3ZjblB3akdtdjI3cnRyN0wtM2VCa2VmdnkxSGNRLUlvb3FES0Fjam5KbVFPZmQtaU9aYnVISzVja280dVZpb1A4YWhQSkJIN21ld1pJTG5IaS04RUdXUQ?oc=5","date":"2023-10-10","type":"trial","source":"prnewswire.com","summary":"Agendia® Names Joyce A. O'Shaughnessy, MD as New Principal Investigator for FLEX Study - prnewswire.com","headline":"Agendia® Names Joyce A. O'Shaughnessy, MD as New Principal Investigator for FLEX Study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPNldLMHRCM0hySjV5Z0k4QzZuUGZmeGhpQkk5TURxYzdzYl9tbXhwZFpkRDh1YXJRTFg1NUtaT3AzV28yV2Z4TUxaTHRoamhQV0RwNF9EVVluRFFLVko5dXJNaVg5QW5OWEVPRGhsTm0zTWtVcV9wN2oxLXl2akpsVS1wY1pULUlwWV9mSkxXMS1TYl9nbHhJQ2dvZ0ZFQTgzOGgxMHI4Y0R5YV94dzZN?oc=5","date":"2022-09-21","type":"pipeline","source":"Fierce Biotech","summary":"Puma pounces on failed Takeda drug, snapping up cancer prospect for knockdown price - Fierce Biotech","headline":"Puma pounces on failed Takeda drug, snapping up cancer prospect for knockdown price","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTFB4bUVWNVdhRHJJRzJQRHphbjlBTnZXSUlJdjFYQWFOUEd1dUY4ajI1SlVKSHJRU1hVRkFqOWg4b0x3QXpfcUxlcWdnWG5TT1VyN3FCOC1wNkdxVGtNMTJxTw?oc=5","date":"2022-03-09","type":"pipeline","source":"NEJM","summary":"Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer - NEJM","headline":"Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxPNG9UbzBNeG5WTnZUb3VRYWIzTHYtbE9NUzNQUV91QzY0aGZ1N1JZYWd6STBZWkxJcWw1anhXT3U3bXVHMHhYVXJKSnFPME1uNDUxaHlfM09aZ1NwSjk5QVdlZW5ITUlGZ05NclBFaXFhcjFWV1VreUtINllJaWZON1JSMHA2VGNsNmZJcnpxWEhtWDhPWXVDbXZrT0pqUUdiV0lrS3QxeWFzZzZFdzRaZHEwRmRGWnZhNmYzQzVrU1o2V3NuckloZUhGTXhoNGFuM0otZU02VnNHdw?oc=5","date":"2021-01-25","type":"pipeline","source":"ascopost.com","summary":"Unexpected Survival Benefit Reported With Trilaciclib in Metastatic Triple-Negative Breast Cancer - ascopost.com","headline":"Unexpected Survival Benefit Reported With Trilaciclib in Metastatic Triple-Negative Breast Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxNRWhnbEU4RkEtYlNyakZTSmwzM0tUakg5NFdlZkM0QVlkRTdvZVVHR2NpNVNUSTdySHREbVQ5QS0wMS1acFFJNFpHMFQ3WjNuRHFqOGt4dzZIQjl5S1hWZVdyYnhQR1FpaXVNT2w2Q3hza3hqXzhUZ3hwVU04UmpNc0VyV0FiSUtnY3NxTk56N09kVnRQU1FGWF9MRExRSnZzOWppRzRWZW1TMzBYdm82djNQc1VsVDJJOHJvWWhRRFBrclJoVTl1b0dRSGYwRFA5NGEyV2w1bXdFVlByRk5VQXlpQzFxdw?oc=5","date":"2020-06-03","type":"pipeline","source":"ascopost.com","summary":"Love of Science and a Family Tragedy Set the Course for This Breast Cancer Researcher - ascopost.com","headline":"Love of Science and a Family Tragedy Set the Course for This Breast Cancer Researcher","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE8xa2xLeUoyeElCUFc2QjVScm81TnBKYy0zUkFRVjVRSGZ5eVFzQmhYb2RVUXR6aUNia3A0ajgtd0JENWJsTGRLM09saWlDb3RNZlBWZE9kT0JlcDNNbEZYbg?oc=5","date":"2016-10-08","type":"pipeline","source":"NEJM","summary":"Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer - NEJM","headline":"Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}